Mupirocin

CAT: 0804-HY-B0958-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0958-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae) . Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis[1][2][3][4][5][6].
CAS Number
[12650-69-0]
Product Name Alternative
BRL-4910A; Pseudomonic acid
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Aminoacyl-tRNA Synthetase; Antibiotic; Bacterial
Type
Natural Products
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Mupirocin.html
Purity
98.34
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O)=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2
Molecular Formula
C26H44O9
Molecular Weight
500.62
Precautions
H302, H315, H319, H335
References & Citations
[1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27 (4) :495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6 (10) :761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42 (3) :272-5.|[4]Twilley D, et al. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. |[5]Ha KR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118 (3) :535-40. |[6]Gilbart J, et al. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993 Jan;37 (1) :32-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Launched

Alternative Products

CatalogName
M022-50MGMupirocin

Popular Products